

HOUSE RESOLUTION NO. 30

Rep. Morse offered the following resolution:

1 A resolution to declare February 2023 as Cholangiocarcinoma
2 Awareness Month in the state of Michigan.

3 Whereas, Cholangiocarcinoma starts in the bile duct, a thin
4 tube, about 4 to 5 inches long, that reaches from the liver to the
5 small intestine. (The major function of the bile duct is to move a
6 fluid called bile from the liver and gallbladder to the small
7 intestine, where it helps digest the fats in food.); and

8 Whereas, There are three types of cholangiocarcinoma:
9 intrahepatic, extrahepatic and perihilar. The mortality rate has
10 increased dramatically in the last decade; and

11 Whereas, An estimated 10,000 people in the United States
12 develop cholangiocarcinoma each year and almost 2 out of 3 people

1 with cholangiocarcinoma are 65 or older when it is found: and

2 Whereas, The chances of survival for patients with bile duct
3 cancer depends to a large extent on its location and how advanced
4 it is when it is found; and

5 Whereas, Patients are typically diagnosed at a late stage due
6 to no validated early method of detection. Symptoms of jaundice,
7 abdominal pain, itchy skin, and weight loss are symptoms that do
8 not usually present until advanced disease progression; and

9 Whereas, Cholangiocarcinoma is a rare cancer. Of the top 8
10 deadliest cancers, 7 are rare. Rare cancers have a 5-year survival
11 rate under 50% with the cholangiocarcinoma 5-year survival rate
12 being approximately 20%; and

13 Whereas, There is currently no cure for
14 cholangiocarcinoma/bile duct cancer; and

15 Whereas, Founded in 2006, in Salt Lake City, Utah, by a family
16 who lost a loved one to cholangiocarcinoma, the Cholangiocarcinoma
17 Foundation has grown to become the leading global resource in
18 research, education, and public awareness; and

19 Whereas, Foundations, research and teaching hospitals, rare
20 cancer advocacy groups, and patient advocacy groups from around the
21 globe have joined forces to recognize February as
22 Cholangiocarcinoma Awareness Month; and

23 Whereas, Increased cholangiocarcinoma advocacy, awareness,
24 research, and education will bring improved outcomes for patients
25 in earlier detection and treatment and potential curative methods;

26 Whereas, The U.S. Food & Drug Administration approved
27 durvalumab (Imfinzi) creating a new standard of care for
28 cholangiocarcinoma patients with the combination of immunotherapy
29 and chemotherapy;

1 Whereas, This body encourages all citizens to educate
2 themselves about the disease by visiting cholangiocarcinoma.org and
3 signing a pledge to help raise awareness in support of
4 Cholangiocarcinoma Awareness Month and residents to remain
5 committed to the continued support of research for treatment and a
6 cure of cholangiocarcinoma; now, therefore, be it

7 Resolved by the House of Representatives, That the members of
8 this legislative body declare February 2023 as Cholangiocarcinoma
9 Awareness Month in the state of Michigan. We recognize all patients
10 and caregivers impacted by this rare, lethal condition.